Table 1.
Descriptive analysis of the 225 studies included in the scoping review
| Lymphopenia available [n (%)] | ||
|---|---|---|
| Studies | 225 | 94 (41.8) |
| Patients | 22,743 | 9141 (40.2) |
| Inclusion of older patients (age ≥ 70 years)a | ||
| Studies | 178 | 77 (43.3) |
| PARPi studied | ||
| Olaparib | ||
| Studies | 94 | 38 (40) |
| Veliparib | ||
| Studies | 67 | 32 (48) |
| Niraparib | ||
| Studies | 24 | 8 (33) |
| Rucaparib | ||
| Studies | 11 | 5 (45) |
| Talazoparib | ||
| Studies | 10 | 5 (50) |
| Iniparib | ||
| Studies | 8 | 2 (25) |
| Fluzoparib | ||
| Studies | 3 | 2 (67) |
| Pamiparib | ||
| Studies | 3 | 1 (33) |
| Othersb | ||
| Studies | 2 | |
| Cancer type | ||
| Gynecological | ||
| Studies | 115 | 42 (37) |
| Multiple | ||
| Studies | 43 | 18 (42) |
| Digestive | ||
| Studies | 18 | 12 (67) |
| Lung | ||
| Studies | 17 | 7 (41) |
| Prostate | ||
| Studies | 11 | 6 (55) |
| Hematologic | ||
| Studies | 6 | 2 (33) |
| Brain | ||
| Studies | 4 | 2 (50) |
| Sarcoma | ||
| Studies | 4 | 3 (75) |
| Head and neck | ||
| Studies | 2 | 1 (50) |
| Melanoma | ||
| Studies | 2 | 1 (50) |
| Otherc | ||
| Studies | 3 | 0 (0) |
PARPi poly(ADP-ribose) polymerase inhibitors
a1 or more patients aged ≥ 70 years were included
bABT-767 and CEP-9722
cEwing sarcoma (n = 1), sarcoma (n = 1), germ line (n = 1)